USANA Health Sciences (USNA)
(Real Time Quote from BATS)
$44.17 USD
-0.58 (-1.30%)
Updated Apr 24, 2024 10:22 AM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Brokerage Reports
0 items in cart
USANA Health Sciences, Inc. [USNA]
Reports for Purchase
Showing records 1 - 20 ( 125 total )
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
With A Challenging Comparison, 1Q:24 Was Likely A Tough Quarter For USNA; Maintain $65 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 21224
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
4Q:23 Results Easily Beat Expectations; Fine-Tune Revenue Assumptions And Temper EPS Estimates
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
4Q:23 Was Likely Hurt By Macro Uncertainty, Foreign Exchange Headwinds; Maintain $68 Target On Expected 2H:24-2025 Earnings Rebound
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
4Q:23 Was Likely Hurt By Macro Uncertainty, Foreign Exchange Headwinds
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 12224
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 1224
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 12223
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Reduced EPS Estimates Imply Sequential Gains Starting In 1Q:24 Driven By Normalizing Trends In China
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 111123
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
View Yesterdays Post-Earnings Selloff As Excessive; Still Expect Sales
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
3Q:23 EPS Just Shy Of Our Forecast, Hurt By A Higher Tax Rate
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 102123
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 101123
Provider: Stock Traders Daily
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Maintain $74 Target Based On Expected 2024 Sales, EPS Rebound, Solid Balance Sheet, Ample Free Cash Flow Prospects
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
3Q:23 Was Likely Impacted By An Uneven Post-Covid China Recovery
Provider: Sidoti CSR
Analyst: Research Department
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for USNA 10123
Provider: Stock Traders Daily
Analyst: Research Department